Sidley Austin is representing Nektar Therapeutics in the transaction, and Goodwin Procter is representing Ampersand Capital Partners. Ampersand has agreed to acquire Nektar’s commercial-scale manufacturing facility...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here